These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34962565)

  • 1. Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder.
    Merlin JS; Khodyakov D; Arnold R; Bulls HW; Dao E; Kapo J; King C; Meier D; Paice J; Ritchie C; Liebschutz JM
    JAMA Netw Open; 2021 Dec; 4(12):e2139968. PubMed ID: 34962565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
    Fitzgerald Jones K; Khodyakov D; Arnold R; Bulls H; Dao E; Kapo J; Meier D; Paice J; Liebschutz J; Ritchie C; Merlin J
    JAMA Oncol; 2022 Aug; 8(8):1107-1114. PubMed ID: 35771550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert consensus-based guidance on approaches to opioid management in individuals with advanced cancer-related pain and nonmedical stimulant use.
    Jones KF; Khodyakov D; Han BH; Arnold RM; Dao E; Morrison J; Kapo J; Meier DE; Paice JA; Liebschutz JM; Ritchie CS; Merlin JS; Bulls HW
    Cancer; 2023 Dec; 129(24):3978-3986. PubMed ID: 37691479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus-based approach to managing opioids, including opioid misuse and opioid use disorder, in patients with serious illness: protocol for a modified Delphi process.
    King C; Arnold R; Dao E; Kapo J; Liebschutz J; Meier D; Paice J; Ritchie C; Czajkowski K; Khodyakov D; Merlin J
    BMJ Open; 2021 May; 11(5):e045402. PubMed ID: 34011593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
    Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
    Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder.
    Smart R; Grant S; Gordon AJ; Pacula RL; Stein BD
    JAMA Health Forum; 2022 Sep; 3(9):e223285. PubMed ID: 36218944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
    Guerra-Alejos BC; Yan Y; Kurz M; Mudalige N; Min JE; Homayra F; Nosyk B
    Addiction; 2024 Aug; 119(8):1453-1459. PubMed ID: 38584294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative Pain and Addiction Interdisciplinary Network (PAIN): protocol of a practice advisory for the perioperative management of buprenorphine using a modified Delphi process.
    Goel A; Azargive S; Weissman JS; Shanthanna H; Ladha KS; Lamba W; Duggan S; Hanlon JG; Di Renna T; Peng P; Clarke H
    BMJ Open; 2019 May; 9(5):e027374. PubMed ID: 31122990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 16. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
    Neumann AM; Blondell RD; Hoopsick RA; Homish GG
    J Addict Dis; 2020; 38(1):33-41. PubMed ID: 31774028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder.
    Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV
    J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.